Financial Performance
5Y price score: 10
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 28.4%
%
ㅤ
By default your notes are visible only to you.
69.5
52-week range
110.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
9.9 %
Dividend Yield TTM
2.9 %
Market cap $
$ 118,126
Price / Earnings TTM
24.4
Price / Book TTM
1.5
PEG TTM
(0.4)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
16.8 %
21.5 %
28.4 %
Free cash flow per share growth
333.9 %
(39.9) %
12.1 %
Earnings per share growth
188.7 %
(74.5) %
(70) %
Founded: 1,863
Employees: 219,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Aug 5, 2026)
1) Strong Financial Performance
- Adjusted operating income reached $5.2 billion, a 35% YoY increase.
- Adjusted earnings per share (EPS) was $2.58, up over 40% YoY.
- Revenue exceeded $106 billion, marking a 7% YoY growth.
- Full-year adjusted EPS guidance raised by $0.60 to a range of $7.90 to $8.10.
- Cash flow from operations expected to be at least $11.5 billion, an increase of $2 billion from prior guidance.
2) Segment Highlights and Growth Drivers
- Health Care Benefits: Revenue of $37 billion, up 3% YoY; adjusted operating income of $2.4 billion. Medical benefit ratio improved to 87.4%.
- Health Services: Revenue of nearly $52 billion, a 11% YoY increase; adjusted operating income of $1.7 billion, up 10% YoY.
- Pharmacy and Consumer Wellness: Revenue of nearly $34 billion, driven by increased prescription volume and contributions from the Rite Aid transaction. Adjusted operating income rose to $1.5 billion, a 10% YoY increase.
3) Strategic Initiatives and Product Plans
- CVS Health is enhancing access to GLP-1 therapies, with a $29 virtual weight management offering and cash pay options starting at $149.
- The launch of the Health100 platform and the AI-powered assistant Haio aims to simplify consumer health care experiences.
- Ongoing investments in technology and AI are expected to improve operational efficiency and enhance consumer engagement.
4) Challenges and Headwinds
- Anticipated headwinds in the 340B program due to dynamic market conditions and manufacturer restrictions.
- Membership declines expected in Caremark due to market exits by health plan customers and a disciplined approach to client renewals.
- The No Surprises Act and independent dispute resolution processes are impacting cost trends and margins, with ongoing frustrations from self-funded employers.
5) Guidance and Outlook
- CVS Health maintains a confident outlook for 2027, projecting adjusted EPS of at least $8.44, reflecting a 13% growth from the adjusted baseline.
- The company is committed to a mid-teens adjusted EPS CAGR from 2025 to 2028, with ongoing investments in technology and operational efficiencies.
- Further details on 2027 headwinds and tailwinds will be provided in the upcoming quarterly calls.
Bottom line: CVS Health's strong Q2 performance, driven by robust revenue growth across all segments and strategic initiatives in technology and consumer health, positions the company favorably for continued growth despite facing some regulatory and market challenges.
Annual Reports, Presentations And IR Contacts
Go to the websiteCVS Health Corporation — Financial Overview, Stock Price, Market Cap
CVS Health Corporation is a company. Founded in 1863. As of October 19, 2026, the company's market capitalization is $118125669200 with a current stock price of $92.36.